SI-BONE, Inc. (NASDAQ:SIBN) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $26.33.

Several analysts have recently weighed in on SIBN shares. Morgan Stanley lowered their price objective on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and issued a $27.00 price objective on shares of SI-BONE in a research note on Tuesday, May 7th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of SI-BONE in a research note on Tuesday, May 7th. Finally, Piper Sandler initiated coverage on shares of SI-BONE in a research note on Thursday, March 28th. They issued an “overweight” rating and a $25.00 price objective for the company.

SI-BONE Stock Up 0.8 %

SI-BONE stock opened at $13.00 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.75 and a current ratio of 9.76. SI-BONE has a 52-week low of $11.76 and a 52-week high of $27.86. The firm has a 50 day moving average price of $13.76 and a two-hundred day moving average price of $16.80. The firm has a market cap of $535.73 million, a price-to-earnings ratio of -11.93 and a beta of 1.20.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings results on Monday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. SI-BONE had a negative net margin of 29.93% and a negative return on equity of 25.14%. The firm had revenue of $37.87 million during the quarter, compared to analyst estimates of $36.45 million. Equities analysts predict that SI-BONE will post -0.95 EPS for the current year.

Insider Activity at SI-BONE

In other news, insider Anthony J. Recupero sold 3,941 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $15.10, for a total value of $59,509.10. Following the completion of the sale, the insider now owns 247,592 shares in the company, valued at approximately $3,738,639.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Anthony J. Recupero sold 3,941 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $15.10, for a total value of $59,509.10. Following the completion of the sale, the insider now owns 247,592 shares in the company, valued at approximately $3,738,639.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Anshul Maheshwari sold 2,441 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.14, for a total transaction of $36,956.74. Following the completion of the sale, the chief financial officer now owns 204,241 shares of the company’s stock, valued at approximately $3,092,208.74. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,647 shares of company stock valued at $129,803. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On SI-BONE

Several institutional investors have recently added to or reduced their stakes in the stock. Kent Lake Capital LLC grew its position in SI-BONE by 5.3% during the first quarter. Kent Lake Capital LLC now owns 421,305 shares of the company’s stock valued at $6,897,000 after buying an additional 21,305 shares during the period. Silvercrest Asset Management Group LLC grew its position in SI-BONE by 13.8% during the first quarter. Silvercrest Asset Management Group LLC now owns 1,060,937 shares of the company’s stock valued at $17,368,000 after buying an additional 128,702 shares during the period. Bellevue Group AG grew its position in SI-BONE by 810.5% during the first quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock valued at $18,661,000 after buying an additional 1,014,756 shares during the period. Price T Rowe Associates Inc. MD grew its position in SI-BONE by 7.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after buying an additional 1,372 shares during the period. Finally, EntryPoint Capital LLC lifted its holdings in SI-BONE by 78.4% during the first quarter. EntryPoint Capital LLC now owns 13,906 shares of the company’s stock valued at $228,000 after purchasing an additional 6,113 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.